Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Overview of attention for article published in Arthritis Research & Therapy, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 3 news outlets

policy: 1 policy source

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 59 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Further evidence for sustained benefits of adalimumab in axSpA

medwireNews, 18 Apr 2018

18-04-2018 | Rheumatology | News | Article medwireNews: Extension results from the ABILITY-1 trial support the long-term…

Spondiloartrite assiale non radiografica, i benefici di adalimumab si mantengono a lungo termine

Pharmastar Italy, 05 Apr 2018

I benefici ottenuti con adalimumab dai pazienti con spondiloartrite assiale non radiografica (nr-axSpA) sono continuati nella…

Adalimumab's Benefits Persist for Spine Disease

MedPage Today, 28 Mar 2018

Action Points Note that this open-label extension study of adalimumab for the treatment of axial spondyloarthritis demonstrated…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.